Results 41 to 50 of about 4,917 (213)

Soluble gC1qR is an autocrine signal that induces B1R expression on endothelial cells [PDF]

open access: yes, 2013
Bradykinin (BK) is one of the most potent vasodilator agonists known and belongs to the kinin family of proinflammatory peptides. BK induces its activity via two G protein-coupled receptors: BK receptor 1 (B1R) and BK receptor 2.
David, H   +10 more
core   +2 more sources

Factor XII – What's important but not commonly thought about

open access: yesResearch and Practice in Thrombosis and Haemostasis, 2019
Factor XII (FXII) becomes a serine protease when blood is exposed to artificial medical surfaces or when pathologic surfaces arise in disease states leading to its autoactivation.
Alvin H. Schmaier, Evi X. Stavrou
doaj   +1 more source

Modulation of the Plasma Kallikrein-Kinin System Proteins Performed by Heparan Sulfate Proteoglycans

open access: yesFrontiers in Physiology, 2017
Human plasma kallikrein-kinin system proteins are related to inflammation through bradykinin. In the proximity of its target cells, high molecular weight kininogen (H-kininogen) is the substrate of plasma kallikrein, which releases bradykinin from H ...
Guacyara Motta, Ivarne L. S. Tersariol
doaj   +1 more source

Dextran sulfate activates contact system and mediates arterial hypotension via B2 kinin receptors [PDF]

open access: yes, 1994
To define some of the mechanisms underlying dextran sulfate (DXS)-induced hypotension, we investigated the effects of either the plasma kallikrein inhibitor des-Pro2-[Arg15] aprotinin (BAY x 4620) or the specific bradykinin B2-receptor antagonist Hoe-140
Cheronis, John C.   +7 more
core   +2 more sources

Detection of surface-adsorbed (lipo)proteins by means of a two-step enzyme-immunoassay: a study on the Vroman effect [PDF]

open access: yes, 1990
In view of reports on the involvement of high-molecular-weight (HMW) kininogen and high-density lipoprotein (HDL) in the Vroman effect, we studied the adsorption of fibrinogen, HMW kininogen, HDL and several other proteins from pooled human plasma and ...
Aken, W.G. van   +3 more
core   +2 more sources

Pathophysiological Aspects of Aging in Venous Thromboembolism: An Update

open access: yesMedicina, 2022
The aim of this review is to highlight all the factors that associate venous thromboembolism (VTE) with aging. Elderly people are characterized by a higher incidence of thrombosis taking into account the co-existing comorbidities, complications and ...
Dimitra Akrivou   +4 more
doaj   +1 more source

Mechanism and therapy of hereditary angioedema typ III and role of the contact system in inflammatory diseases [PDF]

open access: yes, 2014
Combinations of proinflammatory and procoagulant reactions are associated with a variety of disorders affecting the cardiovascular system. Vascular leakage contributes to the pathology of conditions such as, sepsis, allergy and anaphylactic reactions ...
Björkqvist, Jenny
core   +1 more source

Human plasma kallikrein: roles in coagulation, fibrinolysis, inflammation pathways, and beyond

open access: yesFrontiers in Physiology, 2023
Human plasma kallikrein (PKa) is obtained by activating its precursor, prekallikrein (PK), historically named the Fletcher factor. Human PKa and tissue kallikreins are serine proteases from the same family, having high- and low-molecular weight ...
Guacyara Motta   +2 more
doaj   +1 more source

AUTOACTIVATION OF HUMAN PLASMA PREKALLIKREIN

open access: yesThrombosis and Haemostasis, 1987
Incubation of purified human plasma prekallikrein with sulfatides or dextran sulfate resulted in spontaneous activation of prekallikrein as judged by the appearance of amidolytic activity towards the chromogenic substrate H-D-pro-phe-arg-p-nitroanilide (S 2302).
G, Tans   +4 more
openaire   +2 more sources

Switching Long‐Term Prophylaxis to Donidalorsen for Hereditary Angioedema: 1‐Year OASISplus Results

open access: yesAllergy, EarlyView.
This study evaluated the long‐term safety and efficacy of donidalorsen in patients who switched from a long‐term prophylactic treatment (LTP) to donidalorsen with 1‐year outcomes. Patients who switched from LTP to donidalorsen experienced a 67.6% reduction in HAE attack rates over 52 weeks.
Marc A. Riedl   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy